The Centre for Immunology and Infection (CII) has begun a Phase IIa safety study of a new vaccine for the parasitic disease leishmaniasis.
With funding from Wellcome, HYMS researchers at the CII working with colleagues at the Institute of Endemic Diseases in Khartoum have begun a Phase IIa safety study of a new vaccine for the parasitic disease leishmaniasis.
Vaccines can be used to prevent infection or as a therapeutic, harnessing the power of the immune system to overcome an existing infection. In this clinical trial, the vaccine is being tested to see if it is safe to use in patients with a persistent and stigmatising form of skin leishmaniasis (called post kala azar dermal leishmaniasis or PKDL).
If found to be safe, the team have already received funding to progress to a larger Phase IIb trial to evaluate whether vaccination can provide clinical benefit or even cure the disease. The research is being conducted at the Professor El-Hassan Centre for Tropical Medicine in Dooka, Gedaref State, Sudan.
Picture above: The laboratory and clinical study team includes Paul Kaye, Charles Lacey, Mohamed Osman and Rebecca Wiggins from the CII and Ahmed Musa, Eltahir Khalil and Brima Musa of the IEND.
For more information on this project please contact Professor Paul Kaye or Mohamed Osman in the Centre for Infection & Immunology.